Mitochondria in the aetiology and pathogenesis of Parkinson's disease

The Lancet Neurology

Volumn 7, Issue 1, 2008, Pages 97-109

  Schapira, Anthony HV ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CREATINE; DJ 1 PROTEIN; DNA DIRECTED DNA POLYMERASE BETA; DNA DIRECTED DNA POLYMERASE GAMMA; DNA POLYMERASE GAMMA 1; FREE RADICAL; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PTEN INDUCED PUTATIVE KINASE 1; SERINE PROTEINASE OMI; TOXIN; UBIDECARENONE; UBIQUITIN; UNCLASSIFIED DRUG;

BRAIN; BRAIN MITOCHONDRION; CELL DEATH; CLINICAL TRIAL; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FAMILIAL DISEASE; GENE; GENE MUTATION; HUMAN; INTROSPECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; HUMANS; MITOCHONDRIAL DISEASES; MITOCHONDRIAL PROTEINS; MODELS, BIOLOGICAL; PARKINSON DISEASE;

EID: 37049004489     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70327-7     Document Type: Review

References (164)

1. de Lau L., and Breteler M. Epidemiology of Parkinson's disease. Lancet Neurol 5 (2006) 525-535
2. Hughes A., Daniel S., Ben Shlomo Y., and Lees A. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125 (2002) 861-870
3. Warner T., and Schapira A. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 53 suppl 3 (2003) S16-S23
4. Schapira A. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim Biophys Acta 1410 (1999) 159-170
5. Schapira A., Cooper J., Dexter D., et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1 (1989) 1269
6. Kroemer G., Galluzzi L., and Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 87 (2007) 99-163
7. Bindoff L., Birch-Machin M., Cartlidge N., Parker Jr. W., and Turnbull D. Mitochondrial function in Parkinson's disease. Lancet 2 (1989) 49
8. Parker Jr. W., Boyson S., and Parks J. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26 (1989) 719-723
9. Mizuno Y., Ohta S., Tanaka M., et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163 (1989) 1450-1455
10. Schapira A., Mann V., Cooper J., et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55 (1990) 2142-2145
11. Mann V., Cooper J., Daniel S., et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 36 (1994) 876-881
12. Janetzky B., Hauck S., Youdim M., et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett 169 (1994) 126-128
13. Krige D., Carroll M., Cooper J., Marsden C., and Schapira A. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol 32 (1992) 782-788
14. Haas R., Nasirian F., Nakano K., et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 37 (1995) 714-722
15. Mann V., Cooper J., Krige D., et al. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115 (1992) 333-342
16. 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease. J Neurol Sci 125 (1994) 77-81
17. Penn A., Roberts T., Hodder J., et al. Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle. Neurology 45 (1995) 2097-2099
18. Keeney P., Xie J., Capaldi R., and Bennett Jr. J. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26 (2006) 5256-5264
19. Perier C., Tieu K., Guegan C., et al. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci USA 102 (2005) 19126-19131
20. Ikebe S., Tanaka M., Ohno K., et al. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem Biophys Res Commun 170 (1990) 1044-1048
21. Schapira A., Holt I., Sweeney M., et al. Mitochondrial DNA analysis in Parkinson's disease. Mov Disord 5 (1990) 294-347
22. Lestienne P., Nelson I., Riederer P., Reichmann H., and Jellinger K. Mitochondrial DNA in postmortem brain from patients with Parkinson's disease. J Neurochem 56 (1991) 1819
23. Kraytsberg Y., Kudryavtseva E., McKee A., et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 38 (2006) 518-520
24. Bender A., Krishnan K., Morris C., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38 (2006) 515-517
25. Ozawa T., Tanaka M., Ino H., et al. Distinct clustering of point mutations in mitochondrial DNA among patients with mitochondrial encephalomyopathies and with Parkinson's disease. Biochem Biophys Res Commun 176 (1991) 938-946
26. Ikebe S., Tanaka M., and Ozawa T. Point mutations of mitochondrial genome in Parkinson's disease. Brain Res Mol Brain Res 28 (1995) 281-295
27. Shoffner J., Brown M., Torroni A., et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 17 (1993) 171-184
28. Lucking C., Kosel S., Mehraein P., and Graeber M. Absence of the mitochondrial A7237T mutation in Parkinson's disease. Biochem Biophys Res Commun 211 (1995) 700-704
29. Kosel S., Grasbon-Frodl E., Hagenah J., Graeber M., and Vieregge P. Parkinson disease: analysis of mitochondrial DNA in monozygotic twins. Neurogenetics 2 (2000) 227-230
30. Richter G., Sonnenschein A., Grunewald T., Reichmann H., and Janetzky B. Novel mitochondrial DNA mutations in Parkinson's disease. J Neural Transm 109 (2002) 721-729
31. Vives-Bauza C., Andreu A., Manfredi G., et al. Sequence analysis of the entire mitochondrial genome in Parkinson's disease. Biochem Biophys Res Commun 290 (2002) 1593-1601
32. van der Walt J., Nicodemus K., Martin E., et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 72 (2003) 804-811
33. Pyle A., Foltynie T., Tiangyou W., et al. Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann Neurol 57 (2005) 564-567
34. Ross O., McCormack R., Maxwell L., et al. mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish. Exp Gerontol 38 (2003) 397-405
35. Kazuno A., Munakata K., Nagai T., et al. Identification of mitochondrial DNA polymorphisms that alter mitochondrial matrix pH and intracellular calcium dynamics. PLoS Genet 2 (2006) e128
36. Swerdlow R., Parks J., Miller S., et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40 (1996) 663-671
37. Gu M., Cooper J., Taanman J., and Schapira A. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 44 (1998) 177-186
38. Thyagarajan D., Bressman S., Bruno C., et al. A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Ann Neurol 48 (2000) 730-736
39. Rana M., de C., Diaz F., Smeets H., and Moraes C. An out-of-frame cytochrome b gene deletion from a patient with parkinsonism is associated with impaired complex III assembly and an increase in free radical production. Ann Neurol 48 (2000) 774-781
40. Parker Jr. W., and Parks J. Mitochondrial ND5 mutations in idiopathic Parkinson's disease. Biochem Biophys Res Commun 326 (2005) 667-669
41. Ekstrand M., Terzioglu M., Galter D., et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA 104 (2007) 1325-1330
42. Kubo S., Kitami T., Noda S., et al. Parkin is associated with cellular vesicles. J Neurochem 78 (2001) 42-54
43. Shimura H., Hattori N., Kubo S., et al. Immunohistochemical and subcellular localization of parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol 45 (1999) 668-672
44. Stichel C., Augustin M., Kuhn K., et al. Parkin expression in the adult mouse brain. Eur J Neurosci 12 (2000) 4181-4194
45. Shimura H., Hattori N., Kubo S., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25 (2000) 302-305
46. Zhang Y., Gao J., Chung K., et al. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 97 (2000) 13354-13359
47. Imai Y., Soda M., Inoue H., et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105 (2001) 891-902
48. Yamamoto A., Friedlein A., Imai Y., et al. Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. J Biol Chem 280 (2005) 3390-3399
49. Chung K., Thomas B., Li X., et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304 (2004) 1328-1331
50. Kuroda Y., Mitsui T., Kunishige M., et al. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 15 (2006) 883-895
51. Kitada T., Asakawa S., Hattori N., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
52. Lucking C., Durr A., Bonifati V., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 342 (2000) 1560-1567
53. Farrer M., Chan P., Chen R., et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 50 (2001) 293-300
54. Lohmann E., Periquet M., Bonifati V., et al., for the French Parkinson's Disease Genetics Study Group, European Consortium on Genetic Susceptibility in Parkinson's Disease. How much phenotypic variation can be attributed to parkin genotype?. Ann Neurol 54 (2003) 176-185
55. Pramstaller P., Schlossmacher M., Jacques T., et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 58 (2005) 411-422
56. Hayashi S., Wakabayashi K., Ishikawa A., et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 15 (2000) 884-888
57. Goldberg M., Fleming S., Palacino J., et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278 (2003) 43628-43635
58. Palacino J., Sagi D., Goldberg M., et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279 (2004) 18614-18622
59. Casarejos M., Menendez J., Solano R., et al. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 97 (2006) 934-946
60. Greene J., Whitworth A., Kuo I., et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 100 (2003) 4078-4083
61. Muftuoglu M., Elibol B., Dalmizrak O., et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord 19 (2004) 544-548
62. Silvestri L., Caputo V., Bellacchio E., et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 14 (2005) 3477-3492
63. Unoki M., and Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20 (2001) 4457-4465
64. Nakajima A., Kataoka K., Hong M., Sakaguchi M., and Huh N. BRPK, a novel protein kinase showing increased expression in mouse cancer cell lines with higher metastatic potential. Cancer Lett 201 (2003) 195-201
65. Abahuni N., Gispert S., Bauer P., et al. Mitochondrial translation initiation factor 3 gene polymorphism associated with Parkinson's disease. Neurosci Lett 414 (2007) 126-129
66. Valente E., Abou-Sleiman P., Caputo V., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
67. Valente E., Salvi S., Ialongo T., et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 56 (2004) 336-341
68. Hatano Y., Li Y., Sato K., et al. Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol 56 (2004) 424-427
69. Rohe C., Montagna P., Breedveld G., et al. Homozygous PINK1 C-terminus mutation causing early-onset parkinsonism. Ann Neurol 56 (2004) 427-431
70. Beilina A., Van Der B., Ahmad R., et al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci USA 102 (2005) 5703-5708
71. Gandhi S., Muqit M., Stanyer L., et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 129 (2006) 1720-1731
72. Muqit M., Abou-Sleiman P., Saurin A., et al. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem 98 (2006) 156-169
73. Healy D., Abou-Sleiman P., Ahmadi K., et al. The gene responsible for PARK6 Parkinson's disease, PINK1, does not influence common forms of parkinsonism. Ann Neurol 56 (2004) 329-335
74. Groen J., Kawarai T., Toulina A., et al. Genetic association study of PINK1 coding polymorphisms in Parkinson's disease. Neurosci Lett 372 (2004) 226-229
75. Hedrich K., Hagenah J., Djarmati A., et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit?. Arch Neurol 63 (2006) 833-838
76. Bonifati V., Rohe C., Breedveld G., et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65 (2005) 87-95
77. Rogaeva E., Johnson J., Lang A., et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 61 (2004) 1898-1904
78. Grunewald A., Breedveld G., Lohmann-Hedrich K., et al. Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis. Neurogenetics 8 (2007) 103-109
79. Tan E., Yew K., Chua E., et al. PINK1 mutations in sporadic early-onset Parkinson's disease. Mov Disord 21 (2006) 789-793
80. Abou-Sleiman P., Muqit M., McDonald N., et al. A heterozygous effect for PINK1 mutations in Parkinson's disease?. Ann Neurol 60 (2006) 414-419
81. 18F-dopa PET study. Ann Neurol 52 (2002) 849-853
82. Park J., Lee S., Lee S., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441 (2006) 1157-1161
83. Clark I., Dodson M., Jiang C., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441 (2006) 1162-1166
84. Zhang L., Shimoji M., Thomas B., et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet 14 (2005) 2063-2073
85. Nagakubo D., Taira T., Kitaura H., et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 231 (1997) 509-513
86. Takahashi K., Taira T., Niki T., et al. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J Biol Chem 276 (2001) 37556-37563
87. Taira T., Saito Y., Niki T., et al. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 5 (2004) 213-218
88. Canet-Aviles R., Wilson M., Miller D., et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 101 (2004) 9103-9108
89. Bandopadhyay R., Kingsbury A., Cookson M., et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 127 (2004) 420-430
90. Yokota T., Sugawara K., Ito K., et al. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun 312 (2003) 1342-1348
91. Bonifati V., Rizzu P., van Baren M., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
92. Xu J., Zhong N., Wang H., et al. The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum Mol Genet 14 (2005) 1231-1241
93. Shendelman S., Jonason A., Martinat C., Leete T., and Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2 (2004) e362
94. Tang B., Xiong H., Sun P., et al. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum Mol Genet 15 (2006) 1816-1825
95. Goldberg M., Pisani A., Haburcak M., et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45 (2005) 489-496
96. Pisani A., Martella G., Tscherter A., et al. Enhanced sensitivity of DJ-1-deficient dopaminergic neurons to energy metabolism impairment: role of Na+/K+ ATPase. Neurobiol Dis 23 (2006) 54-60
97. Kim R., Smith P., Aleyasin H., et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 102 (2005) 5215-5220
98. Filosto M., Mancuso M., Nishigaki Y., et al. Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase gamma. Arch Neurol 60 (2003) 1279-1284
99. Schapira A. Mitochondrial disease. Lancet 368 (2006) 70-82
100. Luoma P., Melberg A., Rinne J., et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 364 (2004) 875-882
101. Davidzon G., Greene P., Mancuso M., et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol 59 (2006) 859-862
102. Mancuso M., Filosto M., Oh S., and DiMauro S. A novel polymerase gamma mutation in a family with ophthalmoplegia, neuropathy, and Parkinsonism. Arch Neurol 61 (2004) 1777-1779
103. Taanman J., and Schapira A. Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease. Neurosci Lett 376 (2005) 56-59
104. Hudson G., Schaefer A., Taylor R., et al. Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism. Arch Neurol 64 (2007) 553-557
105. Martins L., Morrison A., Klupsch K., et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 24 (2004) 9848-9862
106. Strauss K., Martins L., Plun-Favreau H., et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 14 (2005) 2099-2111
107. Plun-Favreau H., Klupsch K., Moisoi N., et al. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol 9 (2007) 1243-1252
108. Chen L., and Feany M. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8 (2005) 657-663
109. Hsu L., Sagara Y., Arroyo A., et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157 (2000) 401-410
110. Tabrizi S., Orth M., Wilkinson J., et al. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9 (2000) 2683-2689
111. Abeliovich A., Schmitz Y., Farinas I., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000) 239-252
112. Orth M., Tabrizi S., Tomlinson C., et al. G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage. Neurochem Int 45 (2004) 669-676
113. Lee M., Stirling W., Xu Y., et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 99 (2002) 8968-8973
114. Martin L., Pan Y., Price A., et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26 (2006) 41-50
115. Klivenyi P., Siwek D., Gardian G., et al. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis 21 (2006) 541-548
116. Dauer W., Kholodilov N., Vila M., et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 99 (2002) 14524-14529
117. Norris E., Uryu K., Leight S., et al. Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol 170 (2007) 658-666
118. Farrer M., Stone J., Mata I., et al. LRRK2 mutations in Parkinson disease. Neurology 65 (2005) 738-740
119. Gilks W., Abou-Sleiman P., Gandhi S., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365 (2005) 415-416
120. Zabetian C., Samii A., Mosley A., et al. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65 (2005) 741-744
121. Deng H., Le W., Guo Y., et al. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol 57 (2005) 933-934
122. Di Fonzo A., Rohe C., Ferreira J., et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365 (2005) 412-415
123. Kachergus J., Mata I., Hulihan M., et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76 (2005) 672-680
124. Hernandez D., Paisan R., Crawley A., et al. The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett 389 (2005) 137-139
125. Nichols W., Pankratz N., Hernandez D., et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365 (2005) 410-412
126. Aasly J., Toft M., Fernandez-Mata I., et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 57 (2005) 762-765
127. Di Fonzo A., Tassorelli C., De Mari M., et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 14 (2006) 322-331
128. Giasson B., Covy J., Bonini N., et al. Biochemical and pathological characterization of Lrrk2. Ann Neurol 59 (2006) 315-322
129. Gloeckner C., Kinkl N., Schumacher A., et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15 (2006) 223-232
130. Smith W., Pei Z., Jiang H., et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 102 (2005) 18676-18681
131. West A., Moore D., Biskup S., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102 (2005) 1684247
132. Schapira A. The importance of LRRK2 mutations in Parkinson disease. Arch Neurol 63 (2006) 1225-1228
133. Singer T., Salach J., Castagnoli Jr. N., and Trevor A. Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases. Biochem J 235 (1986) 785-789
134. Hantraye P., Brouillet E., Ferrante R., et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nature Med 2 (1996) 1017-1021
135. Betarbet R., Sherer T., MacKenzie G., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 (2000) 1301-1306
136. Hoglinger G., Feger J., Prigent A., et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 84 (2003) 491-502
137. Betarbet R., Canet-Aviles R., Sherer T., et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 22 (2006) 404-420
138. Sherer T., Betarbet R., Stout A., et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22 (2002) 7006-7015
139. Wang X., Li S., Chou A., and Bronstein J. Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease. Neurobiol Dis 23 (2006) 198-205
140. Seaton T., Cooper J., and Schapira A. Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxin. Brain Res 809 (1998) 12-17
141. Champy P., Hoglinger G., Feger J., et al. Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J Neurochem 88 (2004) 63-69
142. Smith P., Cooper J., Govan G., Harding A., and Schapira A. Smoking and mitochondrial function: a model for environmental toxins. Q J Med 86 (1993) 657-660
143. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 53 suppl 3 (2003) S26-S36
144. Thomas P., Cooper J., King R., et al. Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function. J Anat 183 (1993) 451-461
145. Schapira A. Oxidative stress in Parkinson's disease. Neuropathol Appl Neurobiol 21 (1995) 3-9
146. Chan C., Guzman J., Ilijic E., et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447 (2007) 1081-1086
147. McNaught K., Belizaire R., Isacson O., Jenner P., and Olanow C. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179 (2003) 38-46
148. McNaught K., Perl D., Brownell A., and Olanow C. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56 (2004) 149-162
149. Schapira A., Cleeter M., Muddle J., et al. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol 60 (2006) 253-255
150. Zeng B., Bukhatwa S., Hikima A., Rose S., and Jenner P. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann Neurol 60 (2006) 248-252
151. Manning-Bog A., Reaney S., Chou V., et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol 60 (2006) 256-260
152. Bove J., Zhou C., Jackson-Lewis V., et al. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 60 (2006) 260-264
153. Voges D., Zwickl P., and Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68 (1999) 1015-1068
154. Hoglinger G., Carrard G., Michel P., et al. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem 86 (2003) 1297-1307
155. Shults C., Oakes D., Kieburtz K., et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59 (2002) 1541-1550
156. The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68 (2007) 20-28
157. Muller T., Buttner T., Gholipour A., and Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett 341 (2003) 201-204
158. Storch A., Jost W., Vieregge P., et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson's disease. Arch Neurol 64 (2007) 938-944
159. Matthews R., Ferrante R., Klivenyi P., et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157 (1999) 142-149
160. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66 (2006) 664-671
161. Bender A., Koch W., Elstner M., et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 67 (2006) 1262-1264
162. Olanow C., Schapira A., LeWitt P., et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 5 (2006) 1013-1020
163. Schapira A., Bezard E., Brotchie J., et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 5 (2006) 845-854
164. Schapira A. Treatment options in the modern management of Parkinson disease. Arch Neurol 64 (2007) 108:3-108:8